Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical tria...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Front Neurol
Main Authors: Moccia, Marcello, Lanzillo, Roberta, Petruzzo, Martina, Nozzolillo, Agostino, De Angelis, Marcello, Carotenuto, Antonio, Palladino, Raffaele, Brescia Morra, Vincenzo
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Neurology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7311570/
https://ncbi.nlm.nih.gov/pubmed/32625161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00489
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki